The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Complex karyotypes and their prognostic value in CLL
Paolo Ghia, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy discusses the prognostic value of complex karyotypes in chronic lymphocytic leukemia (CLL) and details the results from his team’s analysis on 4,000 samples from CLL patients to evaluate this prognostic value and what these karyotypes may predict. He also notes that these results cannot currently be used in clinical trials, although they will definitely be relevant in the future. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
